Table 3. Association of SNPs rs1054135, rs712, rs7816, rs12050562, rs3748960, rs3654, rs11819488, rs10780691, rs7213430, rs3771286, rs4977544, rs7896, rs7854673, rs3780634, and the risk of disease progression.
| Gene | SNP | Alleles (major/minor) |
MAF | HRa (95% CI) | P | Genetic model | FDR | |
|---|---|---|---|---|---|---|---|---|
| Disease-free | Relapse | |||||||
| FABP4 | rs1054135 | A/G | 0.48 | 0.32 | 0.36 (0.19-0.69) | 0.0012 | ADD | 0.017 |
| KRAS | rs712 | G/T | 0.21 | 0.33 | 2.11 (1.12-3.95) | 0.019 | ADD | 0.247 |
| NTRK2 | rs7816 | T/A | 0.18 | 0.14 | 0.00 (0.00-NA) | 0.031 | REC | 0.372 |
| FBN1 | rs12050562 | C/T | 0.24 | 0.27 | 2.00 (0.92-4.36) | 0.077 | DOM | 0.847 |
| ERBB4 | rs3748960 | T/C | 0.08 | 0.02 | 0.36 (0.08-1.61) | 0.12 | ADD | 1.20 |
| NTRK2 | rs3654 | A/G | 0.17 | 0.22 | 1.55 (0.77-3.12) | 0.22 | ADD | 1.98 |
| ZNF365 | rs11819488 | A/G | 0.19 | 0.21 | 2.56 (0.31-21.06) | 0.39 | REC | 3.12 |
| NTRK2 | rs10780691 | C/T | 0.22 | 0.24 | 0.50 (0.09-2.90) | 0.42 | REC | 2.94 |
| BRIP1 | rs7213430 | A/G | 0.28 | 0.26 | 0.83 (0.47-1.47) | 0.52 | ADD | 3.12 |
| PID1 | rs3771286 | C/T | 0.5 | 0.45 | 0.85 (0.49-1.45) | 0.54 | ADD | 2.70 |
| SLC24A2 | rs4977544 | C/T | 0.05 | 0.03 | 0.69 (0.17-2.82) | 0.59 | REC | 2.26 |
| TAB2 | rs7896 | C/G | 0.06 | 0.05 | 0.64 (0.06-6.86) | 0.71 | REC | 2.13 |
| SLC24A2 | rs7854673 | A/T | 0.06 | 0.06 | 1.25 (0.37-4.20) | 0.72 | REC | 1.44 |
| NTRK2 | rs3780634 | A/G | 0.05 | 0.04 | 1.13 (0.30-4.31) | 0.85 | REC | 0.85 |
Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between SNPs and recurrence & metastasis risk was adjusted for age, tumour size (≤2cm and >2 cm), lymph-node involvement (no and yes), histological type, menopausal status (no and yes), vascular invasion (no and yes), breast or ovarian cancer history (no and yes), taxane/anthracycline-based chemotherapy (yes or no) and radiotherapy (no and yes)